MyFinsight
Home
Blog
About
Gross proceeds from
secondary public offering
$14,888K
(17.93%↑ Y/Y)
Net cash provided by
financing activities
$14,441K
(6.73%↑ Y/Y)
Canceled cashflow
$447K
Net (decrease)
increase in cash and cash...
$6,814K
(278.61%↑ Y/Y)
Canceled cashflow
$7,627K
Commissions paid on
secondary public offering
$447K
(17.94%↑ Y/Y)
Stock-based compensation
expense
$2,877K
(153.70%↑ Y/Y)
Accounts payable and
accrued liabilities
$180K
(112.28%↑ Y/Y)
Amortization of operating
lease right of use...
$145K
(-44.02%↓ Y/Y)
Depreciation expense
$6K
(-57.14%↓ Y/Y)
Maturities of marketable
securities
$2,975K
Purchases of property and
equipment
-$1K
(-104.55%↓ Y/Y)
Net cash used in
operating activities
-$7,604K
(56.10%↑ Y/Y)
Net cash used in
investing activities
-$23K
(-4.55%↓ Y/Y)
Canceled cashflow
$3,208K
Canceled cashflow
$2,976K
Change in fair value of
warrant liability
-$7,977K
(8.54%↑ Y/Y)
Purchases of marketable
securities
$2,999K
Net loss
-$1,722K
(70.70%↑ Y/Y)
Prepaid expense and
other current assets
$936K
(-60.87%↓ Y/Y)
Operating lease liability
-$144K
(47.25%↑ Y/Y)
Amortization of investments
in marketable...
-$33K
Back
Back
Cash Flow
Unicycive Therapeutics, Inc. (UNCY)
Unicycive Therapeutics, Inc. (UNCY)
source: myfinsight.com